Abstract
Conclusions
The above experiments, more rigorous than those previously reported∗ because treatment was purposely withheld until infection was established and then conducted with equal doses of the 2 drugs, show 2-(sulfanilamido)-pyridine slightly superior to sulfanilamide in combatting Type II pneumococcal infections of less than 100 fatal doses in mice and rats.∗ These conclusions are based on survival values only.
Get full access to this article
View all access options for this article.